ADMA Biologics Inc $ADMA Shares Sold by Mutual of America Capital Management LLC

Mutual of America Capital Management LLC trimmed its stake in shares of ADMA Biologics Inc (NASDAQ:ADMA) by 10.9% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 30,668 shares of the biotechnology company’s stock after selling 3,755 shares during the quarter. Mutual of America Capital Management LLC’s holdings in ADMA Biologics were worth $558,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Nuveen LLC acquired a new position in ADMA Biologics in the first quarter valued at $93,543,000. Vaughan Nelson Investment Management L.P. purchased a new position in shares of ADMA Biologics during the 2nd quarter worth approximately $32,786,000. Driehaus Capital Management LLC boosted its stake in shares of ADMA Biologics by 114.9% during the 1st quarter. Driehaus Capital Management LLC now owns 2,946,570 shares of the biotechnology company’s stock worth $58,460,000 after purchasing an additional 1,575,363 shares during the last quarter. Invesco Ltd. boosted its stake in ADMA Biologics by 13.9% in the 1st quarter. Invesco Ltd. now owns 12,866,904 shares of the biotechnology company’s stock worth $255,279,000 after buying an additional 1,570,649 shares during the last quarter. Finally, Russell Investments Group Ltd. raised its stake in ADMA Biologics by 152.7% during the first quarter. Russell Investments Group Ltd. now owns 1,632,675 shares of the biotechnology company’s stock worth $32,392,000 after purchasing an additional 986,666 shares during the period. Hedge funds and other institutional investors own 75.68% of the company’s stock.

ADMA Biologics Price Performance

ADMA opened at $15.60 on Tuesday. The company’s 50-day moving average price is $15.77 and its 200 day moving average price is $18.21. The firm has a market cap of $3.72 billion, a price-to-earnings ratio of 18.14 and a beta of 0.47. The company has a quick ratio of 2.78, a current ratio of 5.33 and a debt-to-equity ratio of 0.21. ADMA Biologics Inc has a fifty-two week low of $13.50 and a fifty-two week high of $25.67.

ADMA Biologics (NASDAQ:ADMA) last issued its quarterly earnings data on Wednesday, August 6th. The biotechnology company reported $0.15 earnings per share for the quarter, beating the consensus estimate of $0.14 by $0.01. The firm had revenue of $121.98 million for the quarter, compared to the consensus estimate of $121.77 million. ADMA Biologics had a net margin of 44.06% and a return on equity of 41.01%. ADMA Biologics’s quarterly revenue was up 13.8% compared to the same quarter last year. During the same period last year, the firm posted $0.13 EPS. As a group, sell-side analysts expect that ADMA Biologics Inc will post 0.51 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings lowered shares of ADMA Biologics from a “buy (b-)” rating to a “hold (c+)” rating in a report on Friday. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $27.67.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.